verici Dx

DELIVERS.

You have high standards, so do we.
You expect more from biomarkers, Tutivia™ delivers.

Tutivia™ is a single test using RNA signature technology, to assist you in taking your patient's personalized post-kidney transplant care to the next level.

Earlier insights for proactive care:

Tutivia™ is the only blood test for acute rejection that can be used at any time, even in the first week after transplant.

Personalization to dynamically inform treatment decisions:

Tutivia™ differentiates transplant rejection from BK nephropathy and generates a patient-centric risk score rather than one derived from generalized population-wide indications.

Reliable testing for all your patients:

Uniquely, Tutivia™ is validated in a broadly diverse clinical patient population, with a full range of kidney donors and recipients, to produce robust results using a data-driven risk score.

YOU WANT EARLIER INSIGHTS FOR PROACTIVE CARE - TUTIVIA™ MAKES IT POSSIBLE.

Acute rejection often happens early. The Verici clinical data reported:[1,2,3]

+ **80%** of clinically indication biopsies were performed in the first 60 days.
+ **69%** of these early biopsies showed acute rejection (AR).
+ **83%** of early biopsies showing AR had a high Tutivia risk score.

- Tutivia is designed to be a **single blood test** detecting RNA expression changes **earlier in the disease course** than later markers of injury such as cfDNA.
- Tutivia can be used **as early as the first week** after the transplant.
- Tutivia provides a patient-centric risk score that can be used proactively and demonstrates **statistically significant improved performance** over serum creatinine while being an **independent predictor** in combination with serum creatinine.

When you receive a high-risk Tutivia™ result, the odds ratio of that patient having acute rejection (AR) is 5.74 over a low-risk result. This high odds ratio increases confidence in making informed treatment decisions.

EARLY | PERSONALIZED | DYNAMIC | RELIABLE

verici Dx

1. L. Gallon, P. O'Connell, A. Chang, M. Donovan. A novel prospective validation trial of multiple blood-based RNA signature assays pre and post kidney transplant to predict rejection. In: American Transplant Congress; June 4-8, 2022; Boston, MA.
2. O. Bestard, J. Augustine, L. Gallon, MJ Ansari, G. La Manna, M. Samaniego, R. Mannon. Clinical performance validation of Tutivia™ biomarker. In: American Society of Nephrology; November 1-6, 2022. Orlando; FL.
3. Publications Submitted

tutivia™ DELIVERS.

You want personalization to dynamically inform treatment decisions - Tutivia™ leads the way.

Why are risk scores important for patient care?

Patient stratification into high and low risk enables clinicians to further personalize their patient care.
Clinicians may utilize risk scores to:

- Assess therapeutic adjustments to balance the risk of rejection with the risk of infection and malignancy.
- Determine the need for further diagnostic testing and timing of biopsies.
- Manage clinical time and frequency of monitoring.

Tutivia™	Other Technologies
The Tutivia RNA signature translates a patient's individual gene expression related to rejection to produce an overall patient risk score.	Derived from population-driven data that may result in imprecise applicability at the patient level.

What makes RNA signatures different?

The instructional and highly dynamic biological function of RNA is reflected in prognostic advantages from RNA signatures in risk score generation. The Tutivia RNA signature is derived from biological systems such as inflammatory response, cell repair and cell metabolism that are highly predictive of identifying all forms of acute rejection. AI-developed algorithms were constructed to exclude confounding factors such as BK nephropathy; this cannot be achieved with natural biomarkers alone.

You want reliable testing for all your patients — Tutivia™ is clinically validated.

You have a complex patient population, and so we clinically validated Tutivia in a non-randomized, prospective, multi-center, blinded, international observational trial with wide inclusion criteria and few exclusions.[1,2,3]

• 32% of kidney donors were high risk, including donors after cardiac death (DCD) and expanded criteria donors (ECD)

• Full spectrum of acute rejection by BANFF 2019 criteria from both indication and protocol biopsies (i.e., T-cell mediated rejection (TCMR), antibody-mediated rejection (ABMR), borderline TCMR, and Mixed)

- 74% Low-Risk and 26% High-Risk with a cut point > 50
- Above this cut point, 60% High-Risk showed AR (PPV)
- Below this cut point, 79% Low-Risk did not show AR (NPV)



Tutivia™ is an in vitro prognostic assay that analyzes the gene expression of multiple RNA biomarkers from peripheral blood collected within 6 months following kidney transplant surgery. A clinically validated cutoff and risk score classifies kidney transplant patients as either low or high risk for clinical and/or sub-clinical acute rejection as determined by histopathology in a kidney biopsy.

Stay up to date with Verici Dx https://www.linkedin.com/company/verici-dx/ @Vericidx

verici Dx | Driven by curiosity. **Delivered by science.** | **p:** +1 (833) 243.4552 **e:** info@vericidx.com | vericiDx.com